This study investigates how the shortage of raw materials and Active Pharmaceutical Ingredients (APIs), affects India's pharmaceutical industry. The report presents a thorough picture of the problem through interviews with industry specialists such as supply chain, production, procurement, and operations managers, as well as production operators, pharmacists, and diabetes patients. According to the study, the lack of raw materials and APIs generates major challenges in the manufacturing of medications, resulting in delays and unfulfilled customer demands. These shortages also have an impact on the availability and cost of essential drugs, including those used to treat diabetes. As a result, people are finding it more difficult to obtain and purchase the medications they require. According to the research, these shortages are also limiting the expansion of India's pharmaceutical business and making it less competitive on the global market. Such shortages may push India to rely more on imports in the long run. The report recommends a few techniques for dealing with these problems. These include obtaining raw materials and APIs from a wide variety of sources, increased communication among industry stakeholders, better planning, and the adoption of a 'Just-in-Case' inventory management system. In brief, this study provides important information for the pharmaceutical professionals, governments, and future researchers. It highlights the importance of strategic planning in ensuring the robustness and worldwide competitiveness of India's pharmaceutical industry during issues like as raw material and API shortages.